Cimetidine may improve survival in colorectal cancer
the ONA take:
According to new research published in the journal ecancermedicalscience, cimetidine, a histamine-2 receptor antagonist (H2RA), can improve survival in colorectal cancer.
Researchers from the Repurposing Drugs in Oncology (ReDO) project have found that cimetidine has positive effects in colorectal cancer, gastric cancer, melanoma, and renal cell carcincoma. Cimetidine would be an effective repurposed drug for cancer as it is very safe and has preclinical and clinical evidence of effectiveness for numerous types of cancer.
Furthermore, cimetidine is cheap and available over-the-counter. Cimetidine, like famotidine and ranitidine, works by inhibiting histamine receptors in the stomach, thereby decreasing the production of gastric acid.
The ReDO project has also found evidence of anti-cancer properties among clarithromycin, diclofenac, mebendazole, nitroglycerin, and itraconazole. Their findings suggest that these anti-cancer properties should be studied in clinical trials, but pharmaceutical companies lack the financial incentives to do so.
They note that repurposed drugs that are accessible, cheap, and have limited adverse effects are good alternatives to treat cancer in low- and middle-income countries and could reduce costs of treating cancer in developed countries.
Cimetidine, a histamine-2 receptor antagonist (H2RA), can improve survival in colorectal cancer.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Immune Thrombocytopenia (Fact Sheet)
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|